Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.39 |
| ▸ | FABP7 | O15540 | 2/20 | 0.39 |
| ▸ | CASP3 | P42574 | 4/20 | 0.38 |
| ▸ | PTGIR | P43119 | 2/20 | 0.37 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.34 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.34 |
| ▸ | CASR | P41180 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21994344 | 1.00 | FABP5 (0.39) | FABP5FABP7CASP3PTGIRPTGDR | |
| SCHEMBL21994733 | 0.87 | FABP5 (0.40) | FABP5FABP7CASP3PTGIRPTGDR | |
| SCHEMBL21994734 | 0.87 | FABP5 (0.40) | FABP5FABP7CASP3PTGIRPTGDR | |
| SCHEMBL30065486 | 0.86 | CASP3 (0.42) | FABP5FABP7CASP3PPARGPPARA | |
| SCHEMBL21994848 | 0.86 | CASP3 (0.42) | FABP5FABP7CASP3PPARGPPARA | |
| SCHEMBL21994849 | 0.86 | CASP3 (0.42) | FABP5FABP7CASP3PPARGPPARA | |
| SCHEMBL30191516 | 0.85 | FABP5 (0.38) | FABP5FABP7CASP3PTGIRPTGDR | |
| SCHEMBL21994818 | 0.84 | FABP5 (0.37) | FABP5FABP7CASP3PTGIRPTGDR | |
| SCHEMBL21994819 | 0.84 | FABP5 (0.37) | FABP5FABP7CASP3PTGIRPTGDR | |
| SCHEMBL30191333 | 0.83 | CASP3 (0.38) | FABP5FABP7CASP3PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230089867-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | NOVARTIS AG (CH) | 2023-03-23 | — | — | US | disclosed |
| EP-3887363-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | Novartis AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| WO-2020110008-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | NOVARTIS AG (CH) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089867-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | PCSK9, PCSK7, PCSK6 | FABP5 3197/4885FABP7 2757/4885CASP3 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.